MIAMI LAKES, Fla., Aug. 3, 2012 /PRNewswire/ -- Fuse Science, Inc. (OTCQB: DROP), (www.fusescience.com) an innovative consumer products company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals, announced today that it will hold a business update teleconference and webcast for shareholders and the investment community on Monday, August 6th, 2012 at 4:30 PM ET.
Fuse Science, Inc. CEO, Brian Tuffin will host the call and will be joined by Rubin Hanan, President and COO and Jeanne Hebert, VP of Marketing and Clinical Research. Among the topics the Fuse executives will discuss include; a new licensing relationship, new distribution progress, the status of its upcoming Drop line of products and the significance of Fuse's clinical research results and next steps.
Interested parties can listen to the live teleconference by dialing (877) 407-0782 from the U.S. or (201) 689-8567 for international callers. Individuals may access the live audio webcast by visiting http://www.investorcalendar.com/IC/CEPage.asp?ID=169461
A replay of the teleconference will be available until August 20th, 2012 which can be accessed by dialing (877) 660-6853 if calling within the United States or (201) 612-7415, if calling internationally. Please enter account #286 and conference ID #398685 to access the replay. A replay of the webcast will also be archived and available within the investor relations section of the company's web site at www.fusescience.com.
In addition, Fuse is pleased to announce that the technical difficulties that consumers were experiencing while ordering EnerJel at its distribution partner GNC's web site (www.gnc.com) have been resolved and product transactions and shipments have resumed.
About Fuse Science, Inc.
Fuse Science, Inc. (OTCQB: DROP), is an innovative consumer products holding company based in Miami Lakes, Florida. Fuse Science holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. The company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly - all in a concentrated "DROP" form that is simply applied under the tongue. The Fuse Science technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. Information about Fuse Science is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873).
Safe Harbor Statement
Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the Company's SEC filings. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.
SOURCE Fuse Science, Inc.